arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Boundless Bio, Inc.

BOLD
$2.90 ▲ +0.05 (+1.75%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
3 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
26
Health
Poor
Bearish
auto_awesome

Analytical Summary

Boundless Bio, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $64.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC -50.9%
FCF / Share $-2.11
Trailing P/E
Price / Book 0.7x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

3-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-58.20M
↑ +11.0%
FCF / Share Free cash flow per share
$-2.11
↑ +43.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 3 years · 13 quarters